Because of its immunodominancy, and because it is conserved in different geographical isolates of Plas-
peptides, either carrier-free or coupled to carrier proteins, was shown to be inducible only by using strong (e.g., Freund's) adjuvants. Furthermore, response to the carrier-free peptide, administered in adjuvant, is genetically restricted to I-Ab mice. In the present paper, we report that high titers of antibodies against the NANP repetitive epitope were obtained in responder C57BL/6 (H-2b) mice when they were primed with live BCG (bacillus Calmette-Gu6rin Mycobacterum tuberculosis var. bovis) and immunized once with the synthetic peptide (NANP)40 coupled to tuberculin purified protein derivative (PPD) without the use ofany adjuvant. This approach also led to the production of high titers of anti-NANP antibodies in ASW (H-2s), B1O.RI (H_2r), BALB/c (H_2d), C3H/He (H_2k), and DBA/1 (H_2q) nonresponder mice after two injections ofthe conjugate. In both cases, BCG priming was obligatory for the induction of antibodies reacting with the synthetic peptide. The levels of anti-NANP antibodies in nonresponder BALB/c mice were demonstrated to be comparable to the levels induced after PPD-(NANP)40 immunization in Freund's complete or incomplete adjuvant. The antibodies induced were also capable of recognizing P. falciparum sporozoites in immunofluorescence assays and, furthermore, these antibodies inhibited the penetration of live sporozoites into human hepatocytes in vitro. This system functioned independently of the subjects' resistance or susceptibility to BCG infection. Given the widespread natural exposure to mycobacterial antigens and the extensive use ofBCG and PPD in the human population, this approach might be envisaged for vaccination with malaria peptides.
Despite their short persistence in the bloodstream after injection by anopheline vectors, malaria sporozoites elicit a species-and stage-specific immune response, which has been shown to be able to confer immune protection in experimental models (1) . Sporozoite-mediated immune protection is a complex phenomenon that involves the intervention of T cells (2) (3) (4) (5) , lymphokines (6, 7) , and antibodies (8) (9) (10) (11) . Antisporozoite antibodies have been shown to predominantly recognize the repetitive sequence present within the major surface antigen of the parasite's circumsporozoite (CS) protein (8, 9) . Because of its immunodominance, and because it is conserved in different geographical isolates ofPlasmodium falciparum (12) , the repetitive sequence of the CS protein, (Asn-Ala-Asn-Pro), [(NANP)J], has been envisaged for the development of an anti-falciparum malaria subunit vaccine.
However, the murine immune response to (NANP), peptides was shown to be genetically restricted to I-Al mice (13, 14) .
The use of carrier proteins was required to induce an anti-NANP immune response in otherwise nonresponsive mice (13, 14) . In both cases, the anti-NANP response was only inducible by using strong (e.g., Freund's) adjuvants, the immunization with (NANP)" constructs in physiological solutions being ineffective (15) . Vaccination trials have been conducted in human volunteers by using recombinant and synthetic NANP constructs. The low level of responsiveness among the human subjects immunized in this manner indicated that further study was necessary before using CS protein analogues as components of an eventual malaria vaccine (16) (17) (18) .
Mycobacteria induce strong T-cell responses and can potentiate immune responses. BCG (bacillus Calmette-Gudrin Mycobacterium tuberculosis var. bovis) is widely used to vaccinate people against tuberculosis (19) , and the tuberculin purified protein derivative (PPD) is currently used to measure the T-cell reactivity in people exposed to tuberculosis or vaccinated with BCG. Previous work by Lachmann et (NANP)40 ELISA. Mice were bled weekly from the periorbital plexus, the serum was separated, and the titers of anti-(NANP)40 antibody were measured in ELISA using the (NANP)40 peptide in the solid phase, as described in detail elsewhere (14) . Samples having titers of <200 in ELISA were considered negative. The results are expressed as the mean ± SEM log1o reciprocal of the last serum dilution positive (A495 -0.2) in the (NANP)40 ELISA.
Immunofluorescence. P. falciparum sporozoites (NF54 strain) were handled as described (21) . Briefly, fresh isolated parasites were deposited on glass slides coated with poly-L-lysine and kept at 4°C for 24 hr in a moist chamber to allow attachment. Antibodies were titrated by standard techniques (21) .
Inhibition of Sporozoite Penetration in Vitro. Human hepatocytes were seeded in eight-chamber Lab-Tek plastic culture wells (Miles) and incubated for 24 hr before inoculation with sporozoites. Salivary glands from Anopheles stephensi mosquitoes, infected with the NF54 strain of P. falciparum, were aseptically dissected, pooled, and disrupted in a glass tissue grinder. Sporozoite number was evaluated in a Neubauer chamber and 4000 parasites per hepatocyte were added to each culture. The percentage inhibition of sporozoite penetration in the presence of test and control mouse sera was then evaluated by a double-staining technique (21) .
RESULTS

Anti-(NANP)40 Antibody Induction in Responder Mice
Without Adjuvant. A first series of experiments was designed to determine the potential for BCG priming followed by PPD-(NANP)4 immunization to induce anti-(NANP)40 antibodies without adjuvant in mice responsive [i.e., capable of producing anti-(NANP)40 antibodies when the carrier-free peptide was injected with adjuvant] to the malaria epitope. C57BL/6 mice (H-2b) genetically responsive to the P. falciparum CS protein NANP repetitive sequence (13, 14) Having determined the applicability of our system to the induction of anti-(NANP)40 antibodies in responder mice, we then questioned whether the same strategy would overcome the genetic restriction to the peptide in nonresponder mice. We also wished to determine the comparative efficacy of our approach to the induction of anti-NANP antibodies with respect to Freund's complete (FCA) and incomplete (FIA) adjuvants.
Hence, the same experimental approach was applied to BCG primed mice of the ASW (H-2s), B1O .RIII (H-2r), BALB/c (H_2d), C3H/He (H-2k), DBA/1 (H-2q), and the responder C57BL/6 (H-2b) strains. Interestingly, after the first conjugate immunization, only the responder C57BL/6 mice conjugate in 500 1I of PBS i.p. On day 35 after BCG infection, the mice were bled from the periorbital plexus and then reimmunized with the PPD-(NANP)40 conjugate. On day 49, the mice were bled again and all the sera were tested for the presence of anti-(NANP)40 antibodies in ELISA as described (14) . instance, the pooled sera gave positive results in an immunofluorescence assay performed on a preparation of whole P.
tntibodies.
Mter the second conjufalciparum sporozoites. In the second, which also evaluated the mouse strains tested produced the biologic activity of the antibodies in vitro, the sera tested he synthetic peptide (Fig. 2) .
inhibited the penetration of P. falciparum sporozoites into observation that anti-(NANP)40 ancultured human liver cells ( (14) and are resistant to BCG infection (i.e., capable of controlling the growth of the bacterium within 24 hr after injection) (22) , and BALB/c mice, which are nonresponders and are susceptible to BCG infection, clearly show that resistance to BCG did not influence the ability of BCG-primed C3H/He mice to produce anti-(NANP)40 antibodies when the injection of the PPD-(NANP)40 conjugate was given 1, 2, or 3 weeks after BCG immunization (Fig. 4) (23) (24) (25) or on the identification of T-cell epitopes on proteins important in the asexual blood stage forms of 'the parasite (26, 27) . Much work on the former strategy has shown that one ofthe T-helper epitopes ofthe CS protein maps to polymorphic regions ofthe molecule (28) (25) .
The addition of T-cell epitopes is not the only means to increase the immunogenicity of a given peptide.' Delivery in liposomes with lipid A (29) or proteosomes as vectors that are potent B-cell mitogens (30) has been shown to ameliorate the immune response to malaria peptides. Augmentation of the immune response to NANP has also been obtained with interleukin 2, suggesting that this cytokine may locally stimulate the few T cells in a nonresponder mouse recognizing the malaria epitope, thus giving rise to a more generalized immune response against the sequence (31) . 'Sensitization with BCG followed by immunization with PPD-(NANP)40 presents several advantages in supplying the T-cell epitopes necessary to overcome genetic restriction of the immune response to the synthetic peptide. PPD is composed of a plethora of mycobacterial epitopes (20) . Thus, a wide variety of T-cell epitopes are linked to (NANP)40. Supplying many varied epitopes at once may, for the present, represent the best method for ensuring adequate T-cell stimulation in a population with a heterogeneous major histocompatibility complex make-up. In addition, we have never observed the phenomenon of epitope-specific suppression with respect to PPD purported to play a role in the nonreactivity toward the NANP epitope cited in other immunization strategies in which other carrier proteins are used (17) . Our system may not lead to a secondary immune response to NANP upon natural exposure to sporozoites, but it presents the advantage of inducing substantial levels of IgG lasting several weeks, thereby directly reaping many of the benefits such a secondary response would entail. Furthermore, the constituents of our system, BCG/PPD, have been sufficiently used, either in tuberculosis vaccination or Mantoux testing, to make one speculate about their use in increasing the immunogenicity ofpeptides in humans. Certainly in depth analysis of the constituents of PPD would be required before trials in humans could be undertaken.
In the long term, cloning the CS protein genes directly into bacteria used for immunization may prove the most efficient method of exposing individuals to the NANP antigen. Already work has shown that mice can be vaccinated with an attenuated strain of Salmonella typhimurium into which the CS gene ofPlasmodium berghei has been introduced and are consequently protected from sporozoite challenge (32) . However, these mice failed to produce anti-NANP antibodies. The shuttle plasmid cloning system is currently being applied to the mycobacteria in the hope of using these potent immunomodulators as vectors for introducing antigens in a new generation of vaccines (33, 34) .
In light of these varied other methods for inducing a strong immune response to NANP, our approach appears simpler. Many individuals in malaria-endemic regions already harbor 
